SCHEMBL2522703

SCHEMBL2522703

CC(C)N(C(C)C)P(OOCCC#N)N(C(C)C)C(C)C

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7081474 0.85 TSHR (0.30) TSHR
SCHEMBL7153188 0.81
SCHEMBL313598 0.81 TSHR (0.31) TSHR
SCHEMBL204034 0.80 TSHR (0.32) TSHR
SCHEMBL29674430 0.78 TSHR (0.31) TSHR
Ammonia Solution, Strong SCHEMBL21828798 0.78 TSHR (0.31) TSHR
SCHEMBL20211370 0.78 TSHR (0.31) TSHR
SCHEMBL30389839 0.74 TSHR (0.34) TSHR
SCHEMBL10169834 0.74
SCHEMBL24487862 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4617279-A1 MODIFIED NUCLEOSIDE HAVING GUANIDINO STRUCTURE IN BRIDGED PART AND METHOD FOR PRODUCING OLIGONUCLEOTIDE USING SAME Luxna Biotech Co., Ltd. (JP) 2025-09-17 EP disclosed
WO-2024190907-A1 PRODUCTION METHODS FOR 2'-O-MODIFIED ADENOSINE PHOSPHORAMIDITE AND INTERMEDIATE THEREOF 日産化学株式会社 2024-09-19 WO disclosed
EP-3862431-B1 METHOD FOR PRODUCING HAIRPIN SINGLE-STRAND RNA MOLECULES TORAY INDUSTRIES (JP) 2024-06-26 EP disclosed
WO-2024101446-A1 MODIFIED NUCLEOSIDE HAVING GUANIDINO STRUCTURE IN BRIDGED PART AND METHOD FOR PRODUCING OLIGONUCLEOTIDE USING SAME ルクサナバイオテク株式会社 2024-05-16 WO disclosed
US-20240110186-A1 METHOD OF PRODUCING HAIRPIN SINGLE-STRANDED RNA MOLECULES TORAY INDUSTRIES, INC. (JP) 2024-04-04 US disclosed
US-11891602-B2 Method of producing hairpin single-stranded RNA molecules TORAY INDUSTRIES, INC. (JP) 2024-02-06 US disclosed
WO-2023027065-A1 METHOD FOR PRODUCING 2'-MODIFIED GUANOSINE COMPOUND 日産化学株式会社 2023-03-02 WO disclosed
US-11518994-B2 Artificial single guide RNA and use thereof BONAC CORPORATION (JP) 2022-12-06 US disclosed
EP-3276003-B1 SINGLE-CHAIN NUCLEIC ACID MOLECULE HAVING DELIVERY FUNCTION AND GENE EXPRESSION CONTROL ABILITY BONAC CORP (JP) 2022-07-20 EP disclosed
US-20210317495-A1 METHOD OF PRODUCING HAIRPIN SINGLE-STRANDED RNA MOLECULES TORAY INDUSTRIES, INC. (JP) 2021-10-14 US disclosed
US-8993738-B2 Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom ISIS PHARMACEUTICALS, INC. (US) 2015-03-31 US disclosed
WO-2014205451-A2 COMPOSITIONS AND METHODS FOR MODULATION OF TARGET NUCLEIC ACIDS ISIS PHARMACEUTICALS, INC. (US) 2014-12-24 WO disclosed
US-20130237697-A1 BUILDING BLOCKS AND METHODS FOR THE SYNTHESIS OF 5-HYDROXYMETHYLCYTOSINE-CONTAINING NUCLEIC ACIDS LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) 2013-09-12 US disclosed
EP-2601204-A2 MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM Isis Pharmaceuticals, Inc. (US) 2013-06-12 EP disclosed
US-20130084576-A1 MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM ISIS PHARMACEUTICALS, INC. (US) 2013-04-04 US disclosed
WO-2011139702-A2 MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM ISIS PHARMACEUTICALS, INC. (US) 2011-11-10 WO disclosed
US-8039611-B2 2′-hydroxyl group-modified ribonucleoside derivatives TOKYO INSTITUTE OF TECHNOLOGY (JP) 2011-10-18 US disclosed
US-20100016574-A1 2'-Hydroxyl Group-Modified Ribonucleoside Derivatives TOKYO INSTITUTE OF TECHNOLOGY (JP) 2010-01-21 US disclosed
EP-2006293-A9 2'-HYDROXYL-MODIFIED RIBONUCLEOSIDE DERIVATIVE Tokyo Institute of Technology (JP) 2009-07-22 EP disclosed
EP-2006293-A2 2'-HYDROXYL-MODIFIED RIBONUCLEOSIDE DERIVATIVE Tokyo Institute of Technology (JP) 2008-12-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130084576-A1 MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM RNMT, HNRNPM, NOP2 TSHR 4513/4885
US-11518994-B2 Artificial single guide RNA and use thereof SLIRP, TRDMT1, RNASEL TSHR 1000/4885
US-20130237697-A1 BUILDING BLOCKS AND METHODS FOR THE SYNTHESIS OF 5-HYDROXYMETHYLCYTOSINE-CONTAINING NUCLEIC ACIDS RNGTT, NSUN2, NT5C3B TSHR 3779/4885
US-20100016574-A1 2'-Hydroxyl Group-Modified Ribonucleoside Derivatives RNASEH1, RNASEL, NSUN2 TSHR 1278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.